tiprankstipranks
Trending News
More News >
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Advertisement

Sarepta Therapeutics (SRPT) AI Stock Analysis

Compare
3,975 Followers

Top Page

SRPT

Sarepta Therapeutics

(NASDAQ:SRPT)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$18.50
▲(0.76% Upside)
Sarepta Therapeutics' overall stock score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. The strategic restructuring and cost-saving measures discussed in the earnings call provide some optimism, but technical indicators and valuation concerns weigh on the score.
Positive Factors
Revenue Growth
Strong revenue contribution from ELEVIDYS indicates robust demand and successful market penetration, supporting long-term growth prospects.
Strategic Restructuring
Cost-saving measures and restructuring efforts aim to improve profitability and operational efficiency, enhancing financial stability over time.
Pipeline Focus
Concentrating on high-impact programs ensures strategic resource allocation, potentially leading to breakthrough therapies and future revenue streams.
Negative Factors
Workforce Reduction
Significant workforce reduction may impact morale and operational capacity, potentially hindering long-term growth and innovation capabilities.
ELEVIDYS Adoption Challenges
Safety concerns and hesitancy in ELEVIDYS adoption could limit revenue growth and market acceptance, affecting long-term sales potential.
Nonambulatory Patient Suspension
Suspension of shipments for nonambulatory patients raises regulatory and safety concerns, potentially delaying market expansion and revenue.

Sarepta Therapeutics (SRPT) vs. SPDR S&P 500 ETF (SPY)

Sarepta Therapeutics Business Overview & Revenue Model

Company DescriptionSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneySarepta Therapeutics generates revenue primarily through the commercialization of its therapeutic products, including its lead drug, Exondys 51, which is used to treat DMD. The company earns money from product sales, royalties, and milestone payments associated with its collaborations and partnerships with other pharmaceutical companies. Additionally, Sarepta has engaged in licensing agreements that provide upfront payments and potential future royalties based on sales of partnered products. The company also benefits from government grants and research funding aimed at advancing its clinical programs.

Sarepta Therapeutics Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant strategic restructuring, cost-saving measures, and a focused pipeline to strengthen Sarepta's financial position and future growth. However, challenges such as workforce reduction, hesitancy in ELEVIDYS adoption, and suspension of nonambulatory ELEVIDYS shipments present significant hurdles.
Q2-2025 Updates
Positive Updates
ELEVIDYS Revenue Contribution
ELEVIDYS generated $282 million in revenue in Q2 2025, contributing significantly to the total net product revenue.
Positive Cash Flow and Financial Position
Ended the quarter with $850 million in cash and equivalents, an increase of $203 million over Q1, ensuring financial flexibility.
Cost Reduction and Strategic Restructuring
Plans to reduce ongoing spending by about $900 million through 2027, with an expected $400 million annual cost savings starting in 2026.
Pipeline Focus and Expansion
Focused pipeline on high-impact programs like FSHD, DM1, SCA2, and Huntington's disease, ensuring funding for these developments.
ELEVIDYS Label Update
Agreed with FDA to include a black box warning for ELEVIDYS, which resolves material issues for the ambulant portion of the label.
Negative Updates
Reduction in Workforce
A reduction in force by about 36% of the workforce, approximately 500 employees, was announced as part of the restructuring.
ELEVIDYS Nonambulatory Patient Suspension
Voluntary suspension of shipments for nonambulatory ELEVIDYS patients due to safety concerns, pending further study and FDA dialogue.
Significant Hesitancy in ELEVIDYS Adoption
Noted hesitancy and canceled appointments for ELEVIDYS following two acute liver failure events in nonambulatory patients.
Pausing of Limb-Girdle Programs
Decision to pause most of the limb-girdle pipeline due to financial constraints, seeking alternative approaches like partnerships.
Company Guidance
During the call, Sarepta provided detailed guidance on its strategic restructuring and financial outlook. The company plans to reduce costs by $900 million through 2027 while maintaining profitability and a cash flow-positive status, ensuring it can address its financial obligations, including the retirement of its 2027 convertible note. Sarepta's strategy focuses on supporting its four approved therapies, including the gene therapy ELEVIDYS, and advancing a targeted pipeline of high-impact development programs for rare diseases. The company aims to achieve annual revenues of $500 million from ELEVIDYS and $900 million from its PMO franchise, totaling over $1.4 billion from its Duchenne franchise. Sarepta also plans to reduce its workforce by approximately 36%, translating to about 500 employees, to align resources with its refocused pipeline. The company ended the quarter with $850 million in cash and cash equivalents, reflecting a $203 million increase over the previous quarter.

Sarepta Therapeutics Financial Statement Overview

Summary
Sarepta Therapeutics shows strong revenue growth but faces significant profitability and cash flow challenges. The company has improved its debt-to-equity ratio, yet persistent losses and negative cash flow growth highlight the need for strategic improvements.
Income Statement
45
Neutral
Sarepta Therapeutics has shown a positive revenue growth rate of 11.11% TTM, indicating a strong upward trajectory in sales. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains robust at 78.85% TTM, but the negative net profit margin of -2.34% TTM highlights ongoing challenges in cost management and operational efficiency.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio has improved to 0.997 TTM, indicating a more balanced capital structure compared to previous years. However, the return on equity remains negative at -4.42% TTM, reflecting ongoing losses. The equity ratio is stable, suggesting a reasonable proportion of assets financed by equity, but the high leverage in past years poses a risk.
Cash Flow
40
Negative
Sarepta Therapeutics faces significant challenges in cash flow management, with a negative free cash flow growth rate of -35.78% TTM. The operating cash flow to net income ratio is also negative, indicating difficulties in converting earnings into cash. Despite this, the free cash flow to net income ratio is positive, suggesting some ability to cover net losses with free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.48B1.90B1.24B933.01M701.89M540.10M
Gross Profit1.96B1.58B1.09B793.02M604.84M476.72M
EBITDA43.97M333.06M-439.20M-582.12M-306.08M-453.38M
Net Income-57.96M235.24M-535.98M-703.49M-418.78M-554.13M
Balance Sheet
Total Assets3.68B3.96B3.26B3.13B3.15B2.98B
Cash, Cash Equivalents and Short-Term Investments800.14M1.35B1.68B1.99B2.12B1.94B
Total Debt1.35B1.34B1.40B1.62B1.14B1.07B
Total Liabilities2.32B2.44B2.41B2.74B2.22B2.22B
Stockholders Equity1.36B1.53B859.34M384.95M928.01M761.76M
Cash Flow
Free Cash Flow-441.55M-342.74M-588.34M-356.17M-481.66M25.26M
Operating Cash Flow-300.75M-205.79M-500.99M-325.35M-443.17M107.47M
Investing Cash Flow376.33M755.56M-165.80M-1.05B495.41M-121.72M
Financing Cash Flow51.40M124.81M125.00M232.51M561.57M682.32M

Sarepta Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.36
Price Trends
50DMA
17.56
Positive
100DMA
23.64
Negative
200DMA
60.17
Negative
Market Momentum
MACD
-0.14
Negative
RSI
50.90
Neutral
STOCH
43.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRPT, the sentiment is Positive. The current price of 18.36 is above the 20-day moving average (MA) of 17.99, above the 50-day MA of 17.56, and below the 200-day MA of 60.17, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 50.90 is Neutral, neither overbought nor oversold. The STOCH value of 43.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRPT.

Sarepta Therapeutics Risk Analysis

Sarepta Therapeutics disclosed 63 risk factors in its most recent earnings report. Sarepta Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sarepta Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
2.11B-23.60-67.11%99.50%65.91%
54
Neutral
2.01B-18.75-17.10%191.53%5.09%
49
Neutral
$1.78B19.61-4.76%64.89%-221.56%
48
Neutral
1.60B-43.908.47%45.85%76.36%
43
Neutral
1.87B-3.41-7.71%
37
Underperform
1.98B-5.842.25%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SRPT
Sarepta Therapeutics
18.36
-106.17
-85.26%
BCRX
BioCryst
7.63
<0.01
0.13%
MESO
Mesoblast
15.86
8.26
108.68%
COGT
Cogent Biosciences
14.16
3.26
29.91%
ARQT
Arcutis Biotherapeutics
17.57
8.21
87.71%
DYN
Dyne Therapeutics
13.15
-20.68
-61.13%

Sarepta Therapeutics Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Sarepta Therapeutics Completes Convertible Notes Exchange
Neutral
Aug 29, 2025

On August 20, 2025, Sarepta Therapeutics entered into exchange agreements with holders of its 1.25% Convertible Senior Notes due 2027, exchanging $700 million of these notes for new 4.875% Convertible Senior Notes due 2030, common stock, and cash. This strategic financial move, completed on August 28, 2025, aims to manage debt maturity and optimize capital structure, potentially impacting the company’s financial flexibility and market positioning.

Private Placements and FinancingBusiness Operations and Strategy
Sarepta Therapeutics Restructures Debt with New Convertible Notes
Neutral
Aug 21, 2025

On August 20, 2025, Sarepta Therapeutics entered into exchange agreements with holders of its 1.25% Convertible Senior Notes due 2027, exchanging approximately $700 million of these notes for new 4.875% Convertible Senior Notes due 2030, shares of common stock, and cash. Additionally, the company engaged in a private placement transaction with J. Wood Capital Advisors LLC for $20 million in common stock, with the issuance of these securities relying on exemptions from registration under the Securities Act. These strategic financial maneuvers are expected to impact the company’s capital structure and provide flexibility in managing its debt obligations.

Executive/Board ChangesBusiness Operations and Strategy
Sarepta Therapeutics Announces Strategic Restructuring Plan
Neutral
Aug 13, 2025

Sarepta Therapeutics announced a strategic restructuring and pipeline prioritization, resulting in the end of Bilal Arif’s employment as Executive Vice President, Chief Technical Operations Officer, effective September 16, 2025. Arif will transition to a Special Advisor role until his employment ends and will continue as a consultant through December 31, 2025. The company has agreed to provide Arif with a severance package and consulting fees, while his equity awards will continue to vest during his consultancy. This move reflects Sarepta’s ongoing efforts to optimize its operations and focus on its core strategic objectives.

Product-Related AnnouncementsLegal ProceedingsBusiness Operations and Strategy
Sarepta Faces FDA Hold on Gene Therapy Trials
Negative
Jul 21, 2025

On July 21, 2025, Sarepta Therapeutics announced that the FDA placed a clinical hold on its investigational gene therapy trials for LGMD, affecting several of its product candidates. This follows a strategic restructuring process announced on July 16, 2025, where the company paused LGMD programs except SRP-9003, for which it completed Phase 3 enrollment and dosing in December 2024. Sarepta plans to discuss with the FDA a potential pathway for accelerated approval of SRP-9003 after the hold is lifted. Additionally, the FDA revoked the platform technology designation for Sarepta’s AAVrh74 platform, initially granted in June 2025.

Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Sarepta Therapeutics Announces Strategic Restructuring Plan
Negative
Jul 16, 2025

On July 14, 2025, Sarepta Therapeutics announced a strategic restructuring plan, including a 36% workforce reduction, to prioritize high-value programs and ensure long-term financial sustainability. The company aims to save approximately $400 million annually and focus on its siRNA platform, while also updating the ELEVIDYS label with a black box warning for acute liver issues. Key executive appointments were made, and the company reported preliminary second-quarter 2025 financial results, with total net product revenue of $513 million.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 27, 2025